Clinical validation of a novel RSV-A challenge model in a controlled human infection study in Europe
Developing an RSV vaccine or antiviral requires confidence before committing to larger, time-consuming trials. Field studies are slow, variable and provide limited control over infection timing, symptom development and viral shedding. Controlled human infection model (CHIM) studies address these limitations by enabling infection under carefully monitored conditions, with intensive longitudinal sampling and standardized evaluation of virological and clinical endpoints.
In this case study, we examine the first-in-human proof-of-concept evaluation of RSV-NICA, a GMP-manufactured RSV-A challenge agent derived from a 2015 Belgian clinical isolate. The study assessed safety, symptom profile, viral kinetics and infectivity across 12 healthy adult participants, supporting the use of RSV-NICA as a clinically relevant platform for early RSV drug and vaccine evaluation.
What you'll find in our case study
- Development of the RSV-NICA challenge agentUnderstand how the agent was derived from a recent clinical isolate, manufactured under GMP conditions and supported by non-clinical stability testing prior to first-in-human use.
- Study design and clinical setupReview the screening criteria, inoculation protocol, quarantine conditions and sampling approach used in the clinical validation of the model in a biosafety level 2 environment.
- Results on attack rate, viral kinetics and symptom profileExamine the virological and clinical findings, including a 100% attack rate observed in the analyzed cohort, the timing of peak viral signal and the mild, self-limiting symptom pattern reported.
- The role of CHIM in early-phase RSV developmentLearn how controlled human infection models can inform early efficacy assessment, dose selection and more informed decision-making before progressing to larger trials.